Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Galcanezumab for Vestibular Migraine

NCT04417361
Conditions
Vestibular Migraine
Interventions
Galcanezumab Prefilled Syringe, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Post-Traumatic Headache
Interventions
Galcanezumab-Gnlm
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Albany, New York
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
Erenumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 66 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
29
States / cities
Newport Beach, California • Palo Alto, California • Santa Monica, California + 25 more
Completed Phase 4 Interventional Results available

Erenumab for Idiosyncratic Facial Pain

NCT04249427
Conditions
Facial Pain, Rhinosinusitis
Interventions
Erenumab Prefilled Syringe, Placebo
Drug · Other
Lead sponsor
David Jang, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Migraine
Interventions
Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Long Beach, California • National City, California + 36 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

NCT02792517
Conditions
Headache, Migraine
Interventions
Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
4
States / cities
Anaheim, California • Cypress, California • Dallas, Texas + 1 more
Conditions
Migraine, Episodic Migraine, Chronic Migraine, Headache
Interventions
CGRP antibody or gepant
Drug
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Conditions
Migraine
Interventions
Erenumab, Placebo, PACAP-38 Challenge Agent
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Anaheim, California
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 37 more
Terminated Phase 2 Interventional Results available

Erenumab For Treatment of Hemicrania Continua

NCT04303845
Conditions
Hemicrania Continua
Interventions
Erenumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 66 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder

NCT04884763
Conditions
Temporomandibular Disorder
Interventions
Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments, Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Migraine
Interventions
Galcanezumab, Erenumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Waterbury, Connecticut
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
Erenumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
34
States / cities
La Jolla, California • Newport Beach, California • San Francisco, California + 30 more
Completed Phase 4 Interventional Results available

Efficacy of Erenumab on Functional Impact of Migraine

NCT04465357
Conditions
Migraine
Interventions
Erenumab-Aooe 140 MG/ML [Aimovig]
Drug
Lead sponsor
Merle Diamond
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • City of Saint Peters, Missouri • Springfield, Missouri
Conditions
Cranial Nerve Injury, Oropharyngeal Cancer
Interventions
Prednisone, Ajovy, Manual Therapy, IOPI device
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

Aimovig Pregnancy Exposure Registry

NCT06150781
Conditions
Migraine
Interventions
erenumab-aooe
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,842 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Fibromyalgia
Interventions
Erenumab, Saline
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portsmouth, Virginia
Conditions
Chronic Migraine
Interventions
Emgality 120 MG in 1 ML Prefilled Syringe
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brookline, Massachusetts
Conditions
Post-Traumatic Headache
Interventions
Erenumab, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Conditions
Migraine
Interventions
Erenumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey